Education
About Us
Working with TipRanks
Follow Us
Nucana Plc (NCNA)
NASDAQ:NCNA
NCNA Stock Chart & Stats
$3.33
-$0.06(-4.88%)
At close: 4:00 PM EST
$3.33
-$0.06(-4.88%)
Day’s Range― - ―
52-Week Range$2.00 - $267.80
Previous CloseN/A
Volume88.96K
Average Volume (3M)174.33K
Market Cap
$8.95M
Enterprise Value-$15.26M
Total Cash (Recent Filing)$25.25M
Total Debt (Recent Filing)$136.00K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,906,479
10 Day Avg. Volume84,221
30 Day Avg. Volume174,327
Financial Highlights & Ratios
PEG Ratio1.57
Price to Book (P/B)189.59
Price to Sales (P/S)0.00
P/FCF Ratio-58.15
Enterprise Value/Market Cap-1.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intellectual Property ProtectionThe composition-of-matter patent in China plus a global portfolio (>85 issued patents) materially strengthens exclusivity for NUC-7738. Durable IP protection supports long-term commercialization strategy, increases licensing/partnering leverage, and defends future revenue opportunities if clinical success occurs.
Clinical Efficacy Signals For Lead ProgramsRepeated clinical activity and a favorable safety profile in PD-1 inhibitor–resistant melanoma, including partial responses and durable disease control, increase the probability of a registrational pathway for NUC-7738. Persistent positive signals materially de-risk development and enhance partnership and commercialization prospects.
Low Financial Leverage And RunwayVery low debt reduces refinancing and covenant risk for a pre-revenue biotech, providing financial flexibility to advance clinical programs. Management's stated runway into 2029 implies capital to fund multiple value-driving milestones, lowering near-term dilution risk and enabling strategic partnering or registration planning.
Bears Say
No Revenue And Sustained Negative Cash FlowThe company has no product revenue and consistently negative operating and free cash flow, reflecting ongoing burn to fund R&D. This structural funding gap necessitates recurrent external financing, which can dilute shareholders and heighten execution risk if capital markets tighten or clinical timelines slip.
Eroding Equity Base And Negative ROECumulative losses have materially reduced equity and total assets since 2020, producing deeply negative returns on equity. This erosion constrains the firm's ability to absorb setbacks, increases dependence on new capital, and weakens balance-sheet resilience over multi-year development cycles.
High Binary Clinical And Commercialization RiskAs a clinical-stage company with limited commercial infrastructure and a small workforce, NuCana's long-term success depends on a few binary clinical outcomes and external partnerships. Trial failures, delays, or inability to scale commercial operations would have outsized, lasting negative impacts on prospects.
Nucana News
NCNA FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was $2.00 and its highest was $267.80 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is $8.95M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is Mar 19, 2026 which is in 14 days.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on Nov 13, 2025. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 1,906,479 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -2.292%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in NCNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nucana Plc
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
8.30% Other Institutional Investors
91.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---